ReviewFrontiers in medicine2024
Therapy of IgA nephropathy: time for a paradigm change.
Review in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of sibeprenlimab in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials.BMC nephrology · 2026Pooled it
- Efficacy and safety of BAFF/APRIL dual antagonists in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials.BMC nephrology · 2025Pooled it
- Toward a Treatment Goal Framework for Emerging Therapies in IgAN: Implications for Future Research.Kidney international reports · 2026Article
- Twelve-month real-world outcomes of sparsentan in a multicenter Spanish IgA nephropathy cohort.Clinical kidney journal · 2026Article
- Efficacy and safety of sibeprenlimab in IgA nephropathy: interim analysis of the China cohort in the phase 3 VISIONARY trial.Clinical kidney journal · 2026Article
- Plasma Proteomics in IgA Nephropathy: From Circulating Biomarkers to Molecular Endotypes.Cells · 2026Review
- Long-term real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors.Clinical kidney journal · 2026Article
- Segmental Glomerulosclerosis Subclassification in the Oxford Classification System (MEST-C) Improves the International IgA Nephropathy Prediction Tool.Journal of clinical medicine · 2026Article
- Inhibition of p65 NF-κB enhances production of galactose-deficient IgA1 through suppression ofbioRxiv : the preprint server for biology · 2026Article
- From data to drug: the translational impact of RaDaR, the UK national registry of rare kidney diseases.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Review
- IgA Nephropathy: Mechanisms, Risk Stratification, and Precision Therapy.Diagnostics (Basel, Switzerland) · 2026Review
- Real-world multicenter evidence on Nefecon for attenuating proteinuria and kidney function decline in IgA nephropathy.Frontiers in immunology · 2026Observational
- Immunoglobulin A Nephropathy With Associated Thrombotic Microangiopathy: Biopsy and Clinical Case Series.Clinical medicine insights. Case reports · 2026Article
- Comparison of efficacy and safety of systemic glucocorticoids and Nefecon in IgA nephropathy patients: a real-world retrospective cohort study.Frontiers in immunology · 2026Article
- Tonsillar Tfh cells contribute to the pathogenesis of IgA nephropathy in collaboration with memory B cells.Frontiers in immunology · 2026Article
- Prognostic value of the MEST-C score in long-term outcomes of immunoglobulin A nephropathy patients: Insights from a developing country.World journal of nephrology · 2025Article
- Defining Disease Modification in IgA Nephropathy: Toward a Paradigm Shift in Management.Kidney international reports · 2025Review
- Targeting B cells in IgA nephropathy: from pathogenic insight to therapeutic horizon.Clinical kidney journal · 2025Article
- Review
- TESTING for the Best Biomarker in IgA Nephropathy.Clinical journal of the American Society of Nephrology : CJASN · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulin A nephropathy (IgAN) often has a poor outcome, with many patients reaching kidney failure within their lifetime. Therefore, the primary goal for the treatment of IgAN should be to reduce nephron loss from the moment of diagnosis. To achieve this, IgAN must be recognized and treated as both a chronic kidney disease and an immunological disease. Agents that have received US Food and Drug Administration and European Medicines Agency approval for the treatment of IgAN include modified-release/targeted-release formulation budesonide (Nefecon) and sparsentan, a selective dual endothelin-A and angiotensin II receptor type 1 antagonist. Other agents, including selective endothelin receptor antagonists, selective or combined APRIL and BAFF antagonists, and a vast array of complement inhibitors are being investigated for the treatment of IgAN. Furthermore, treatment combinations are also being studied, including sodium-glucose cotransporter-2 inhibitors with endothelin receptor antagonists. Due to the complexity of IgAN, combination treatment, rather than a single-agent approach, may provide maximum benefit. With the number of treatments for IgAN likely to increase, combinations allowing safe and effective treatment to halt progression to kidney failure seem within grasp. While trials evaluating combinations are ongoing, more are needed to pave the way for a comprehensive IgAN treatment strategy. Furthermore, an approach to IgAN treatment in which agents are combined early to achieve rapid induction of remission and prevent unnecessary and irreversible nephron loss is required. Following remission, treatments may be adjusted and stripped back as necessary in the maintenance phase with close monitoring. This review discusses the current status of IgAN treatment and explores future strategies to improve outcomes for patients with IgAN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.